Shares of Praxis Precision Medicines dropped 48% Friday morning following mixed Phase II results for ulixacaltamide (PRAX-944), which is being studied as a treatment for essential tremor (ET).
https://www.pharmalive.com/wp-content/uploads/2023/03/BioSpacetremors3-3-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-03 12:37:462023-03-03 12:37:46Praxis shares fall 48% following mixed data for essential tremor candidate
